These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
48. Relationship between the Biofilm-Forming Capacity and Antimicrobial Resistance in Clinical Donadu MG; Mazzarello V; Cappuccinelli P; Zanetti S; Madléna M; Nagy ÁL; Stájer A; Burián K; Gajdács M Microorganisms; 2021 Nov; 9(11):. PubMed ID: 34835509 [TBL] [Abstract][Full Text] [Related]
49. In vitro activity of ampicillin-sulbactam against clinical multiresistant Acinetobacter baumannii isolates. Gales AC; Sader HS; Sinto S; Santos OP; Mendes CM J Chemother; 1996 Dec; 8(6):416-9. PubMed ID: 8981180 [TBL] [Abstract][Full Text] [Related]
50. Biofilm formation and antibiotic sensitivity in Hu S; Lv Y; Xu H; Zheng B; Xiao Y Front Cell Infect Microbiol; 2022; 12():953780. PubMed ID: 35967866 [No Abstract] [Full Text] [Related]
51. [Distribution of blaOXA genes in Acinetobacter baumannii strains: a multicenter study]. Ciftci IH; Aşık G; Karakeçe E; Oksüz L; Yağcı S; Sesli Çetin E; Ozdemir M; Atasoy AR; Koçoğlu E; Gül M; Kurtoğlu MG; Köksal Çakırlar F; Seyrek A; Berktaş M; Gültepe B; Ayyildiz A Mikrobiyol Bul; 2013 Oct; 47(4):592-602. PubMed ID: 24237428 [TBL] [Abstract][Full Text] [Related]
52. Prevalence of metalo- β-lactamase-producing (MBL) Acinetobacter species in a tertiary care hospital. Kaur A; Gupta V; Chhina D Iran J Microbiol; 2014 Feb; 6(1):22-5. PubMed ID: 25954487 [TBL] [Abstract][Full Text] [Related]
53. Acinetobacter baumannii nosocomial infections. Sieniawski K; Kaczka K; Rucińska M; Gagis L; Pomorski L Pol Przegl Chir; 2013 Sep; 85(9):483-90. PubMed ID: 24133105 [TBL] [Abstract][Full Text] [Related]
54. Multidrug-resistant acinetobacter infection and their susceptibility patterns in a tertiary care hospital. Rit K; Saha R Niger Med J; 2012 Jul; 53(3):126-8. PubMed ID: 23293410 [TBL] [Abstract][Full Text] [Related]
55. In Vivo and In Vitro Efficacy of Minocycline-Based Combination Therapy for Minocycline-Resistant Acinetobacter baumannii. Yang YS; Lee Y; Tseng KC; Huang WC; Chuang MF; Kuo SC; Lauderdale TL; Chen TL Antimicrob Agents Chemother; 2016 Jul; 60(7):4047-54. PubMed ID: 27114274 [TBL] [Abstract][Full Text] [Related]
56. Molecular characterization and antimicrobial susceptibility of Acinetobacter baumannii isolates obtained from two hospital outbreaks in Los Angeles County, California, USA. Warner WA; Kuang SN; Hernandez R; Chong MC; Ewing PJ; Fleischer J; Meng J; Chu S; Terashita D; English L; Chen W; Xu HH BMC Infect Dis; 2016 May; 16():194. PubMed ID: 27146090 [TBL] [Abstract][Full Text] [Related]
57. Comparison of in vitro activities of levofloxacin, ciprofloxacin, ceftazidime, cefepime, imipenem, and piperacillin-tazobactam against aerobic bacterial pathogens from patients with nosocomial infections. Huang SS; Lee SC; Lee N; See LC; Tsai MH; Shieh WB J Microbiol Immunol Infect; 2007 Apr; 40(2):134-40. PubMed ID: 17446961 [TBL] [Abstract][Full Text] [Related]
58. Comparative in vitro antimicrobial susceptibilities and synergistic activities of antimicrobial combinations against carbapenem-resistant Acinetobacter species: Acinetobacter baumannii versus Acinetobacter genospecies 3 and 13TU. Sheng WH; Wang JT; Li SY; Lin YC; Cheng A; Chen YC; Chang SC Diagn Microbiol Infect Dis; 2011 Jul; 70(3):380-6. PubMed ID: 21558048 [TBL] [Abstract][Full Text] [Related]
59. Biofilm formation is not associated with worse outcome in Acinetobacter baumannii bacteraemic pneumonia. Wang YC; Huang TW; Yang YS; Kuo SC; Chen CT; Liu CP; Liu YM; Chen TL; Chang FY; Wu SH; How CK; Lee YT Sci Rep; 2018 May; 8(1):7289. PubMed ID: 29740176 [TBL] [Abstract][Full Text] [Related]
60. Molecular Detection of Class-D OXA Carbapenemase Genes in Biofilm and Non-Biofilm Forming Clinical Isolates of Acinetobacter baumannii. Azizi O; Shakibaie MR; Modarresi F; Shahcheraghi F Jundishapur J Microbiol; 2015 Jan; 8(1):e21042. PubMed ID: 25789134 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]